NIKKEI 225
38,855.37 -44.65 (-0.11%) HANG SENG
18,821.16 -6.19 (-0.03%) CRUDE OIL
79.66 +1.94 (+2.50%) GOLD FUTURES
2,357.60 +23.10 (+0.99%) DOW
38,794.70 -274.89 (-0.70%) Bitcoin GBP
53,090.41 -1,842.23 (-3.35%)
MRK Jan 2026 140.000 call
| Previous close | 11.00 |
| Open | 8.75 |
| Bid | 9.50 |
| Ask | 9.65 |
| Strike | 140.00 |
| Expiry date | 2026-01-16 |
| Day's range | 8.75 - 9.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 162 |
BenzingaMerck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
Simply Wall St.Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...
Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
RAHWAY, N.J., May 28, 2024--Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer
